

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equality issues were identified during the appraisal process.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No equality issues were identified by the Committee.
--

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

Not applicable.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the preliminary recommendations do not have an adverse impact on people with disabilities.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equality issues have been raised during the appraisal.

Approved by Associate Director (name): Helen Knight

Date: 27/09/2016

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised during consultation

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

Issue date: January 2017

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations do not make it more difficult in practice for a specific group to access the technology compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the recommendations do not have an adverse impact on people with disabilities.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No, because no equality issues were raised during this appraisal.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 25 November 2016

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

Issue date: January 2017